Evidence map›Paper›PMID 40233243›Full record

ArticleOcular immunology and inflammation2025

Effectiveness of Frequently Used TNF Inhibitors vs. Conventional Immunosuppressive Therapies for Noninfectious Uveitis.

Sapna S Gangaputra, Craig W Newcomb, Gui-Shuang Ying, Kurt A Dreger, Tonetta Fitzgerald, Pichaporn Artornsombudh, Srishti Kothari, Teresa L Liesegang, James T Rosenbaum, H Nida Sen and 19 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Ocular immunology and inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Genomic network analysis links uveitis with systemic inflammatory diseases.medRxiv : the preprint server for health sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sapna S GangaputraVanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Craig W NewcombCenter for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Gui-Shuang YingDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kurt A DregerDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Tonetta FitzgeraldDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Pichaporn ArtornsombudhDepartment of Ophthalmology, Somdech Phra Pinklao Hospital, Royal Thai Navy, Bangkok, Thailand.
Srishti KothariDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Teresa L LiesegangDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
James T RosenbaumDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
H Nida SenLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Eric B SuhlerDepartment of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Jennifer E ThorneDepartment of Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nirali P BhattDepartment of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, USA.ORCID 0000-0002-6612-5653
Douglas A JabsDepartment of Ophthalmology, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Grace A Levy-ClarkeLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Careen Y LowderDepartment of Ophthalmology Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Debra A GoldsteinDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Gary N HollandDepartment of Ophthalmology, Ocular Inflammatory Disease Center, Jules Stein Eye Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Glenn J JaffeDepartment of Ophthalmology, Duke University, Durham, North Carolina, USA.
Janet L DavisDepartment of Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute, Miami, Florida, USA.ORCID 0000-0001-6395-5881
Nisha R AcharyaDepartment of Ophthalmology, F.I. Proctor Foundation, University of California San Francisco School of Medicine, San Francisco, California, USA.
Paul A LatkanyDepartment of Ophthalmology, New York Eye and Ear Infirmary/Icahn School of Medicine at Mt. Sinai, New York, New York, USA.
Russell W ReadDepartment of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Sunir J GargMid-Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Yannek I LiedermanDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jeanine M BuchanichSchool of Public Health, Center for Occupational Biostatistics and Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
John H KempenDepartment of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-2967-4792
For The Systemic Immunosuppressive Therapy For Eye Diseases Site Cohort Study Research Group

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Outcomes of uveitic cataract and uveitic glaucoma surgeryR21EY032592 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GANGAPUTRA, SAPNA S · 2021 to 2022
$488k
NEI NIH HHS R01 EY014943NEI NIH HHS R21 EY032592
6 · The paper itself

Abstract

purposeTo compare the corticosteroid sparing efficacy of frequently used antimetabolites to tumor necrosis factor (TNF) inhibitors in the management of noninfectious ocular inflammation.

methodsRetrospective analysis of patients with noninfectious uveitis on conventional antimetabolite (methotrexate, mycophenolate mofetil, azathioprine,or leflunomide, "CONV") or a TNF inhibitor (adalimumab or infliximab, "TNFi") with active inflammation or more than 7.5 mg daily prednisone. Eyes were assessed in three groups: CONV only, TNFi only and combination of both (COMB). Cox regression models compared treatment success, adjusted for age, race, smoking, anatomic location of uveitis, duration of uveitis and visual acuity. Corticosteroid sparing success was defined as: inactive or slightly active uveitis on <=7.5 mg daily oral prednisone and <=2 drops of prednisolone acetate 1%.

resultsThere were 1475 eligible patients in the analysis. By 6 and 12 months, respectively, the Cox model-predicted, percentage success was 27.6% and 44.9% for the CONV group; 34.2% and 53.9% in the TNFi group and 39.9% and 61.1% for the COMB group. COMB was more likely than CONV to achieve success (adjusted HR 1.58 (95% confidence interval (CI), 1.28, 1.95,

conclusionOur results suggest COMB is more effective than CONV at achieving disease quiescence and corticosteroid sparing success among patients with active noninfectious uveitis. More research is needed to determine if TNFi alone is superior to CONV for uveitic corticosteroid-sparing.

Indexed as

AntimetabolitesImmunosuppressive AgentsTumor Necrosis Factor-alphaUveitisAdalimumabAdultAgedAzathioprineDrug Therapy, CombinationFemaleFollow-Up StudiesGlucocorticoidsHumansInfliximabIsoxazolesMaleAdalimumabAntimetabolitesAzathioprineGlucocorticoidsImmunosuppressive AgentsInfliximabIsoxazolesMethotrexateMycophenolic AcidPrednisoneTumor Necrosis Factor-alphaAntimetabolitesimmunosuppressionTNF inhibitoruveitis

Identifiers

PMID40233243
PMCPMC12286736

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.